Recursion Pharmaceuticals マネジメント
マネジメント 基準チェック /14
現在、CEO に関する十分な情報がありません。
主要情報
Chris Gibson
最高経営責任者
US$8.6m
報酬総額
| CEO給与比率 | 6.5% |
| CEO在任期間 | 11yrs |
| CEOの所有権 | 2.5% |
| 経営陣の平均在職期間 | 1.4yrs |
| 取締役会の平均在任期間 | 10.2yrs |
経営陣の近況
Recent updates
Recursion: No News Isn't Good News When It Comes To Vanilla Pipeline
Nov 20Analysts Are Betting On Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) With A Big Upgrade This Week
Nov 10
Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Share Price Could Signal Some Risk
Nov 08Recursion: AI Is Only As Good As The Data
Sep 11Recursion: Path Forward For REC-994 Remains Despite Mixed Response
Sep 04Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 12Recursion Pharmaceuticals: AI-Driven 'TechBio' With Upcoming Catalysts
Aug 01Recursion Pharmaceuticals: More Of A TechBio Industrializing Drug Discovery
Jun 24Recursion Pharmaceuticals: Catalysts Are Coming And Success Is A Must
Jun 14Revenues Not Telling The Story For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) After Shares Rise 25%
May 22Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 12Revisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rate
Apr 10Recursion: Exercising Caution Prior To Q3 Data Release (Rating Downgrade)
Mar 20Recursion Pharmaceuticals (NASDAQ:RXRX) Is Using Debt Safely
Jan 31Recursion Pharmaceuticals: More Hype Than Substance Amid Signs Of Progress
Jan 12Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues
Dec 09What You Need To Know About The Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analyst Downgrade Today
May 09CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$378m |
| Jun 30 2024 | n/a | n/a | -US$375m |
| Mar 31 2024 | n/a | n/a | -US$354m |
| Dec 31 2023 | US$9m | US$561k | -US$328m |
| Sep 30 2023 | n/a | n/a | -US$293m |
| Jun 30 2023 | n/a | n/a | -US$260m |
| Mar 31 2023 | n/a | n/a | -US$249m |
| Dec 31 2022 | US$6m | US$498k | -US$239m |
| Sep 30 2022 | n/a | n/a | -US$247m |
| Jun 30 2022 | n/a | n/a | -US$234m |
| Mar 31 2022 | n/a | n/a | -US$212m |
| Dec 31 2021 | US$674k | US$485k | -US$186m |
| Sep 30 2021 | n/a | n/a | -US$147m |
| Jun 30 2021 | n/a | n/a | -US$124m |
| Mar 31 2021 | n/a | n/a | -US$99m |
| Dec 31 2020 | US$3m | US$270k | -US$87m |
報酬と市場: Chrisの 総報酬 ($USD 8.61M ) は、 US市場 ($USD 5.54M ) の同規模の企業の平均を上回っています。
報酬と収益: Chrisの報酬は増加しましたが、会社は利益を上げていません。
CEO（最高経営責任者
Chris Gibson (41 yo)
11yrs
在職期間
US$8,613,208
報酬
Dr. Christopher C. Gibson, Ph.D. also known as Chris, is Director of Cellino Biotech, Inc. from October 2024. Dr. Gibson is a Co-Founder of Recursion Pharmaceuticals Inc and serves as its Chief Executive O...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Co-Founder | 11yrs | US$8.61m | 2.5% $ 40.9m | |
| Co-Founder & Director | 11.8yrs | US$292.74k | 2.46% $ 40.2m | |
| Chief Medical Officer | 1.4yrs | US$4.53m | 0.019% $ 307.0k | |
| CFO & President of Recursion UK | no data | データなし | データなし | |
| Chief Operating Officer | no data | データなし | データなし | |
| Vice President of Finance & Accounting | no data | データなし | データなし | |
| Chief Technology Officer | 4.8yrs | データなし | データなし | |
| Chief Scientific Officer | no data | データなし | データなし | |
| Senior Director of Investor Relations | 2.5yrs | データなし | データなし | |
| Chief Legal Officer & General Counsel | 1.1yrs | データなし | データなし | |
| Chief Communications Officer | 2.5yrs | データなし | データなし | |
| Chief People and Impact Officer | no data | データなし | データなし |
1.4yrs
平均在職期間
44.5yo
平均年齢
経験豊富な経営陣: RXRXの経営陣は 経験豊富 とはみなされません ( 1.4年の平均在職年数)。これは新しいチームを示唆しています。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Co-Founder | 11yrs | US$8.61m | 2.5% $ 40.9m | |
| Co-Founder & Director | 11.8yrs | US$292.74k | 2.46% $ 40.2m | |
| Chief R&D Officer | less than a year | データなし | データなし | |
| Member of Business Advisory Panel | 10yrs | データなし | データなし | |
| Member of Business Advisory Panel | 10.4yrs | データなし | データなし | |
| Chairman of Therapeutics Advisory Board | 3.3yrs | データなし | データなし | |
| Independent Chairman | 4.7yrs | US$302.74k | 0.013% $ 220.1k | |
| Co-Founder & Independent Director | 11yrs | US$300.25k | 1.11% $ 18.1m | |
| Independent Director | 6.3yrs | US$21.25k | 0.0033% $ 53.5k | |
| Member of Scientific and Technical Advisory Board | 10.6yrs | データなし | データなし | |
| Member of Scientific & Technical Advisory Board | 10.6yrs | データなし | データなし | |
| Independent Director | 8.2yrs | US$307.74k | 0.032% $ 530.9k |
10.2yrs
平均在職期間
61yo
平均年齢
経験豊富なボード: RXRXの 取締役会 は経験豊富で 経験豊富 です ( 10.2年の平均在任期間)。